Physician profile
Annie Peter
NPI 1922051317
$9,317.87
in general payments reported to CMS, 2019-2025
33 companies · $867 in 2025
The $867 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,997 · 2020: $1,194 · 2021: $998 · 2022: $1,234 · 2023: $1,555 · 2024: $1,473 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,881 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,880.75 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,868.00 | 2019-2025 | Aveir, Cardiomems, Perclose Prostyle |
| Impulse Dynamics (USA) INC. | $1,257.78 | 2022-2025 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $1,229.13 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $886.36 | 2019-2024 | Xarelto |
| Amgen INC. | $735.60 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $707.53 | 2019-2025 | Watchman Flx, Bodyguardian |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $558.95 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $317.70 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $295.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $173.89 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $172.11 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $134.35 | 2019-2022 | |
| Esperion Therapeutics, INC. | $130.10 | 2020-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $116.06 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $103.56 | 2021-2025 | Verquvo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $102.98 | 2019-2022 | |
| Cvrx, INC. | $97.48 | 2023-2024 | Barostim Neo System |
| W. L. Gore & Associates, INC. | $78.54 | 2019-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $60.44 | 2022-2023 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.36 | 2020-2023 | Jardiance |
| Medtronic, INC. | $41.50 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $28.38 | 2024 | Arcalyst |
| Inspire Medical Systems, INC. | $17.02 | 2024 | Inspire |
| Regeneron Pharmaceuticals, INC. | $16.80 | 2019 | |
| Scpharmaceuticals INC. | $16.80 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $15.61 | 2025 | Opsumit, Uptravi |
| Genzyme Corporation | $15.02 | 2022 | |
| Medtronic Vascular, INC. | $14.90 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.84 | 2019 | |
| Astellas Pharma US INC | $14.05 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.17 | 2019 | |
| Preventice Services, LLC | $12.78 | 2020 | |
| Angiodynamics, INC. | $11.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Annie Peter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.